Bevacizumab for advanced breast cancer Journal Article
| Authors: | Goldfarb, S. B.; Traina, T. A.; Dickler, M. N. |
| Article Title: | Bevacizumab for advanced breast cancer |
| Abstract: | Tumor angiogenesis is an important step in breast cancer development, progression, invasion and metastasis. Pro-angiogenic factors such as VEGF regulate angiogenesis and are targets for drug development. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination with either paclitaxel or docetaxel has prolonged progression-free survival and increased response rates in the first-line treatment of patients with metastatic breast cancer. This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer. |
| Keywords: | treatment outcome; vascular endothelial growth factor a; clinical trial; disease course; review; angiogenesis inhibitor; bevacizumab; antineoplastic agents; clinical trials as topic; antineoplastic agent; metastasis; randomized controlled trial; antineoplastic combined chemotherapy protocols; randomized controlled trials as topic; pathology; breast neoplasms; monoclonal antibody; standard; antibodies, monoclonal; disease progression; breast tumor; vasculotropin a; neoplasm metastasis; taxoids; angiogenesis inhibitors; taxoid |
| Journal Title: | Women's Health |
| Volume: | 6 |
| Issue: | 1 |
| ISSN: | 1745-5057 |
| Publisher: | Future Medicine |
| Date Published: | 2010-01-01 |
| Start Page: | 17 |
| End Page: | 25 |
| Language: | English |
| PUBMED: | 20001867 |
| PROVIDER: | scopus |
| DOI: | 10.2217/whe.09.71 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work